13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001440771
Total reported value
$177.3M
$177.3M
25 檔
43.8%
According to the latest 13F quarterly dataset, Stonepine Capital Management, LLC managed an equity portfolio of $177.3M at the end of Q2 2024, spanning 25 distinct U.S. exchange-listed positions.
Stonepine Capital Management, LLC executed strategic sector rebalancing during Q2 2024, establishing 12 new positions while fully exiting 7 holdings and trimming 8 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ADMA | Adma Biologics Inc | Stock-Healthcare | 19.07% | +1.16% | -45.43% | |
| 2 | ✓ | Alimera Sciences Inc | Stock-Other | 17.81% | — | -13.31% | |
| 3 | EOLS | Evolus Inc | Stock-Other | 16.41% | +4.41% | -38.02% | |
| 4 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 10.97% | — | +23.21% | |
| 5 | RVNCEUR | Revance Therapeutics Inc | Stock-Other | 6.57% | — | +41.68% | |
| 6 | XOMA | Xoma Royalty Corporation | Stock-Other | 5.41% | -0.87% | EXIT | |
| 7 | ANIK | Anika Therapeutics Inc | Stock-Other | 3.82% | — | +171.37% | |
| 8 | TELA | Tela Bio Inc | Stock-Other | 2.68% | +0.48% | -9.09% | |
| 9 | RIGL | Rigel Pharmaceuticals Inc | Stock-Other | 2.29% | — | — | |
| 10 | ✓ | Optinose Inc | Stock-Other | 2.23% | — | — | |
| 11 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 1.93% | — | — | |
| 12 | SCPH | Scpharmaceuticals Inc | Stock-Other | 1.67% | — | -5.61% | |
| 13 | AUPH | Aurinia Pharmaceuticals Inc | Stock-Other | 1.56% | — | — | |
| 14 | MIST | Milestone Pharmaceuticals In | Stock-Other | 1.49% | — | -15.26% | |
| 15 | AYTU | Aytu Biopharma Inc | Stock-Other | 1.26% | +0.24% | — | |
| 16 | EYEGEUR | Kiora Pharmaceuticals Inc | Stock-Other | 0.77% | — | — | |
| 17 | TORCEUR | Adicet Bio Inc | Stock-Other | 0.67% | — | +330.56% | |
| 18 | SRZN | Surrozen Inc | Stock-Other | 0.66% | -0.38% | EXIT | |
| 19 | XGN | Exagen Inc | Stock-Other | 0.60% | — | -6.74% | |
| 20 | ✓ | Stock-Other | 0.58% | — | — | ||
| 21 | APRE | Aprea Therapeutics Inc | Stock-Other | 0.51% | — | — | |
| 22 | TSVT* | 2seventy Bio Inc | Stock-Other | 0.35% | — | — | |
| 23 | ETON | Eton Pharmaceuticals Inc | Stock-Other | 0.33% | — | — | |
| 24 | IRWD | Ironwood Pharmaceuticals Inc | Stock-Other | 0.29% | — | — | |
| 25 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 0.07% | -0.89% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ✓ | Alimera Sciences Inc | +5.3% | -13.31% | Trim |
| 2 | ANIK | Anika Therapeutics Inc | +2.6% | +171.37% | Add |
| 3 | RIGL | Rigel Pharmaceuticals Inc | +2.3% | NEW | New buy |
| 4 | ✓ | Optinose Inc | +2.2% | NEW | New buy |
| 5 | ACRS | Aclaris Therapeutics Inc | +1.9% | NEW | New buy |
| 6 | AUPH | Aurinia Pharmaceuticals Inc | +1.6% | NEW | New buy |
| 7 | ADMA | Adma Biologics Inc | +1.1% | -45.43% | Trim |
| 8 | LKFT | Lakefront Biotherapeutic-adr | +0.9% | +23.21% | Add |
| 9 | EYEGEUR | Kiora Pharmaceuticals Inc | +0.8% | NEW | New buy |
| 10 | SRZN | Surrozen Inc | +0.7% | NEW | New buy |
| 11 | ✓ | +0.6% | NEW | New buy | |
| 12 | XOMA | Xoma Royalty Corporation | +0.6% | -1.43% | Trim |
| 13 | APRE | Aprea Therapeutics Inc | +0.5% | NEW | New buy |
| 14 | TORCEUR | Adicet Bio Inc | +0.4% | +330.56% | Add |
| 15 | TSVT* | 2seventy Bio Inc | +0.4% | NEW | New buy |
| 16 | ETON | Eton Pharmaceuticals Inc | +0.3% | NEW | New buy |
| 17 | IRWD | Ironwood Pharmaceuticals Inc | +0.3% | NEW | New buy |
| 18 | AYTU | Aytu Biopharma Inc | +0.1% | — | Unchanged |
| 19 | XGN | Exagen Inc | +0.1% | -6.74% | Trim |
| 20 | ACAD | Acadia Pharmaceuticals Inc | +0.1% | NEW | New buy |
| 21 | SCPH | Scpharmaceuticals Inc | -0.1% | -5.61% | Trim |
| 22 | SCYXEUR | Scynexis Inc | -0.1% | EXIT | Sold out |
| 23 | IOBTQ | Io Biotech Inc | -0.2% | EXIT | Sold out |
| 24 | RZLT | Rezolute Inc | -0.3% | EXIT | Sold out |
| 25 | TELA | Tela Bio Inc | -0.4% | -9.09% | Trim |
| 26 | MIST | Milestone Pharmaceuticals In | -0.6% | -15.26% | Trim |
| 27 | XERS | Xeris Biopharma Holdings Inc | -1.1% | EXIT | Sold out |
| 28 | RVNCEUR | Revance Therapeutics Inc | -1.1% | +41.68% | Add |
| 29 | RIGLUSD | Rigel Pharmaceuticals Inc | -1.2% | EXIT | Sold out |
| 30 | CALC | Calcimedica Inc | -1.7% | EXIT | Sold out |
| 31 | NKTREUR | Nektar Therapeutics | -2.6% | EXIT | Sold out |
| 32 | EOLS | Evolus Inc | -13.3% | -38.02% | Trim |
According to official SEC Form 13F filings, Stonepine Capital Management, LLC reported a total U.S. public equity portfolio value of $177.3M across 25 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ADMA, ALIMERA SCIENCES INC, EOLS) accounted for 43.8% of total reported equity market value during Q2 2024.
Top New Position Initiated
RIGL
市值: $2.5M
Top Position Liquidated / Trimmed
NKTREUR
前期市值: $3.3M
During Q2 2024, Stonepine Capital Management, LLC's top holdings by market value included ADMA (19.1%)、ALIMERA SCIENCES INC (17.8%)、EOLS (16.4%). The largest single position, ADMA, represented 19.1% of total portfolio value.
In Q2 2024, Stonepine Capital Management, LLC made 31 total portfolio adjustments, initiating 12 new buys, adding to 4 positions, trimming 8 holdings, and fully liquidating 7 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.